Aegis claims that the excipients present in Intravail increase intranasal bioavailability to levels comparable to subcutaneous injection making it an effective, more convenient alternative.
Phylogica is using this technology to further develop its Phylomer peptides, which it believes are the ideal size for nasal delivery and will benefit from the advantages offered by Intravail.
Ed Maggio, CEO of Aegis, said: “Intranasal delivery is the most validated non-injectable means of delivering peptides since several peptides including calcitonin, desmopressin, and nafarelin have been approved and marketed for years.
“Intranasal formulations have been shown to increase market share by more than 30 fold over the corresponding injectable formulations, because patients overwhelmingly prefer to avoid injections if possible in favour of other delivery approaches.”
The companies will offer their combined services to pharmas that are looking to develop intranasal peptide formulations against a specific target.
Joining two techs
Aegis and Phylogica’s collaboration will utilise their respective propriety technologies, which both claim offer significant advantages when compared to competitors.
Intravail consists of transmucosal absorption enhancement agents that are “safe, odourless, tasteless, non-toxic, non-irritating, non-denaturing, and non-mutagenic” and metabolised to CO2 and H2O after delivery.
The technology is capable of delivering therapeutics up to 30,000 Daltons molecular weight and can be used for administration routes other than intranasal, such as ocular, pulmonary and transdermal, according to Aegis.
In addition Intravail is compatible with standard, off-the-shelf nasal delivery systems and consequently clients do not have to invest in special manufacturing equipment.
This will now be used to deliver therapeutics taken from Phylogica’s Phylomer peptides, which the company claims are quicker to manufacture easier to deliver than antibodies.